IMRA News and Press, IMARA Inc. From 08/25/20

The European Commission has designated Imara's (NASDAQ: IMRA )  IMR-687 as Orphan drug for sickle cell disease. More news on: IMARA Inc., Healthcare stocks news, Read more ...

BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the European C...

Gainers:  Comstock Mining (NYSEMKT: LODE ) +128% . More news on: Comstock Mining Inc., RISE Education Cayman Ltd, IMARA Inc., Stocks on the move, , Read more ...

TG Therapeutics reports development for Umbralisib TG Therapeutics Inc. ( TGTX ) reported that the FDA has accepted its New Drug Application for umbralisib. The drug candidate will be reviewed under the Priority Review pathway. It had been granted Breakthrough Therapy tag for treating ma...

IMARA Inc. (IMRA) Q2 2020 Results Earnings Conference Call August 14, 2020, 08:30 AM ET Company Participants Rahul Ballal - Chief Executive Officer Michael Gray - Chief Financial and Chief Operating Officer Conference Call Participants Yigal Nochomovitz - Citi Group Joseph ...

Imara (NASDAQ: IMRA ) : Q2 GAAP EPS of -$0.59 misses by $0.04 . More news on: IMARA Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial Reported Phase 2a interim safety and efficacy data at the European Hematology Association Annual Congress and promising clinical ...

Imara (NASDAQ: IMRA ) has dosed first patient in Ardent Phase 2b trial of IMR-687 for adult patients with sickle cell disease. Topline data from the trial is expected in the next quarter. More news on: IMARA Inc., Healthcare stocks news, Read more ...

BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced dosing of the first...

BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wi...